FDA Approves AMOXICILLIN AND CLAVULANATE POTASSIUM — USAntibiotics, LLC

USAntibiotics, LLC announced on Tuesday that the FDA has granted approval for AMOXICILLIN AND CLAVULANATE POTASSIUM, oral dosage form NDA050785, with a designated 180-day exclusivity period. This new entry into the high-volume antibiotics market positions the company to compete aggressively against branded competitors, offering potential price disruption in the TAMIFLU derivatives sector.